Skip to main content
Caplight Logo









Okomera

Okomera

Private
ParisHealthcare & Life Scienceshttps://okomera.com/

Last Round

Grant

Oct 21, 2024

Total Funding Raised

$12.8M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Okomera is a biotechnology research company that develops an automated organoid screening platform using microfluidics and AI to accelerate drug discovery and personalized cancer treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

organoid screening platformhigh-throughput screeningdrug discoverypersonalized cancer therapymicrofluidicspatient-derived organoidsprecision oncologycancer organoidstumoroidslab automationphenotypic screening3D cell cultureorganoid-on-a-chipbiotech equipmentbenchtop instrumentpreclinical researchrazor and blade model

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Okomera Comparables

Compare Okomera with similar companies based on industry and business-model similarity.

Okomera comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CN Bio
77%
Cellply
76%
Xilis
76%

Okomera Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantOct 21, 2024
SeedDec 20, 2023

Key People

Founding team and executive leadership

Raphaël Tomasi

Co-founder & CTO

Founding Team

Silvère Lucquin

CEO

Executive Team

Okomera Investors

Notable investors and investment history

Okomera investors
InvestorRounds
Berkeley SkyDeckSeed
ResonanceSeed
BpifranceGrant
IQ-EQSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors increased 63% MoM.

  • Jul 17, 2025

    Grew 19% QoQ, from 27 to 32 employees.

Okomera Filings

Explore SEC and related filing metadata, where available.

Okomera filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Okomera's valuation, stock price, and market status.

Is Okomera a public or private company?

Okomera is a private company.

What is the current stock price of Okomera?

Okomera is a private company with no public stock price. No recent secondary market data is available.

How much is Okomera worth (valuation)?

Valuation information for Okomera is not publicly available.

Can I buy Okomera stock?

Okomera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Okomera's last funding round?

Okomera's most recent funding round was Grant on October 21, 2024.

Who are the main investors in Okomera?

Key investors in Okomera include Resonance.

Will Okomera IPO soon?

No public IPO plans have been announced for Okomera.

How can I track Okomera secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Okomera's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersParis
Employee Range24
Year Founded2020
Last FundingOct 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?